Alpha-actnin-4 (ACTN4) selectively affects the DNA double-strand breaks repair in non-small lung carcinoma cells.
ACTN4
DNA repair
Etoposide resistance
Homologous recombination (HR)
Non-homologous end joining (NHEJ)
Non-small cell lung cancer (NSCLC)
Journal
Biology direct
ISSN: 1745-6150
Titre abrégé: Biol Direct
Pays: England
ID NLM: 101258412
Informations de publication
Date de publication:
07 12 2022
07 12 2022
Historique:
received:
08
11
2022
accepted:
30
11
2022
entrez:
8
12
2022
pubmed:
9
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
ACTN4 is an actin-binding protein involved in many cellular processes, including cancer development. High ACTN4 expression is often associated with a poor prognosis. However, it has been identified as a positive marker for platinum-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC). The goal of our study was to investigate the involvement of ACTN4 in the NSCLC cells' response to the genotoxic drugs. We generated H1299 cells with the ACTN4 gene knock-out (ACTN4 KO), using the CRISPR/Cas9 system. The resistance of the cells to the cisplatin and etoposide was analyzed with the MTT assay. We were also able to estimate the efficiency of DNA repair through the DNA comet assay and gamma-H2AX staining. Possible ACTN4 effects on the non-homologous end joining (NHEJ) and homologous recombination (HR) were investigated using pathway-specific reporter plasmids and through the immunostaining of the key proteins. We found that the H1299 cells with the ACTN4 gene knock-out did not show cisplatin-resistance, but did display a higher resistance to the topoisomerase II inhibitors etoposide and doxorubicin, suggesting that ACTN4 might be somehow involved in the repair of DNA strand breaks. Indeed, the H1299 ACTN4 KO cells repaired etoposide- and doxorubicin-induced DNA breaks more effectively than the control cells. Moreover, the ACTN4 gene knock-out enhanced NHEJ and suppressed HR efficiency. Supporting the data, the depletion of ACTN4 resulted in the faster assembly of the 53BP1 foci with a lower number of the phospho-BRCA1 foci after the etoposide treatment. Thus, we are the first to demonstrate that ACTN4 may influence the resistance of cancer cells to the topoisomerase II inhibitors, and affect the efficiency of the DNA double strand breaks repair. We hypothesize that ACTN4 interferes with the assembly of the NHEJ and HR complexes, and hence regulates balance between these DNA repair pathways.
Sections du résumé
BACKGROUND
ACTN4 is an actin-binding protein involved in many cellular processes, including cancer development. High ACTN4 expression is often associated with a poor prognosis. However, it has been identified as a positive marker for platinum-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC). The goal of our study was to investigate the involvement of ACTN4 in the NSCLC cells' response to the genotoxic drugs.
RESULTS
We generated H1299 cells with the ACTN4 gene knock-out (ACTN4 KO), using the CRISPR/Cas9 system. The resistance of the cells to the cisplatin and etoposide was analyzed with the MTT assay. We were also able to estimate the efficiency of DNA repair through the DNA comet assay and gamma-H2AX staining. Possible ACTN4 effects on the non-homologous end joining (NHEJ) and homologous recombination (HR) were investigated using pathway-specific reporter plasmids and through the immunostaining of the key proteins. We found that the H1299 cells with the ACTN4 gene knock-out did not show cisplatin-resistance, but did display a higher resistance to the topoisomerase II inhibitors etoposide and doxorubicin, suggesting that ACTN4 might be somehow involved in the repair of DNA strand breaks. Indeed, the H1299 ACTN4 KO cells repaired etoposide- and doxorubicin-induced DNA breaks more effectively than the control cells. Moreover, the ACTN4 gene knock-out enhanced NHEJ and suppressed HR efficiency. Supporting the data, the depletion of ACTN4 resulted in the faster assembly of the 53BP1 foci with a lower number of the phospho-BRCA1 foci after the etoposide treatment.
CONCLUSIONS
Thus, we are the first to demonstrate that ACTN4 may influence the resistance of cancer cells to the topoisomerase II inhibitors, and affect the efficiency of the DNA double strand breaks repair. We hypothesize that ACTN4 interferes with the assembly of the NHEJ and HR complexes, and hence regulates balance between these DNA repair pathways.
Identifiants
pubmed: 36476259
doi: 10.1186/s13062-022-00354-6
pii: 10.1186/s13062-022-00354-6
pmc: PMC9730676
doi:
Substances chimiques
Topoisomerase II Inhibitors
0
Doxorubicin
80168379AG
ACTN4 protein, human
0
Actinin
11003-00-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
40Subventions
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 075-15-2021-600
Informations de copyright
© 2022. The Author(s).
Références
Biol Direct. 2021 Aug 4;16(1):11
pubmed: 34348766
Cell Death Differ. 2022 May;29(5):946-960
pubmed: 35361964
Cell Death Differ. 2022 May;29(5):961-971
pubmed: 35396345
Cell Death Differ. 2022 May;29(5):972-982
pubmed: 35444234
Ann Oncol. 2013 Oct;24(10):2594-2600
pubmed: 23899839
J Biol Chem. 2011 Jan 21;286(3):1850-9
pubmed: 21078666
Nat Cell Biol. 2007 Jun;9(6):675-82
pubmed: 17486118
J Vis Exp. 2010 Sep 08;(43):
pubmed: 20864925
Int J Mol Sci. 2021 Jul 30;22(15):
pubmed: 34360968
Oncogene. 2013 Jan 24;32(4):462-70
pubmed: 22370640
J Cell Sci. 2012 Aug 1;125(Pt 15):3529-34
pubmed: 22553214
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731):
pubmed: 28847827
J Biol Chem. 2006 Nov 17;281(46):35070-80
pubmed: 16980305
Cell Biosci. 2015 Aug 18;5:41
pubmed: 26288717
Cell Cycle. 2018;17(15):1917-1930
pubmed: 30109812
Curr Med Chem. 2003 Feb;10(3):257-66
pubmed: 12570712
Acta Biomater. 2021 Apr 1;124:327-335
pubmed: 33556606
J Biol Chem. 2015 Jan 2;290(1):338-49
pubmed: 25411248
Biol Direct. 2021 Dec 9;16(1):25
pubmed: 34886882
Biomark Med. 2017 Sep;11(9):721-731
pubmed: 28658966
J Cell Biol. 1998 Mar 23;140(6):1383-93
pubmed: 9508771
Cell Cycle. 2018;17(5):616-626
pubmed: 29251177
Cell Death Differ. 2021 Nov;28(11):3036-3051
pubmed: 34059798
J Exp Med. 2010 Apr 12;207(4):855-65
pubmed: 20368578
Cancer Med. 2014 Jun;3(3):613-22
pubmed: 24574362
Cell Death Differ. 2021 Jun;28(6):1865-1879
pubmed: 33462409
Oncotarget. 2015 Sep 22;6(28):25843-55
pubmed: 26317544
Nat Genet. 2000 Mar;24(3):251-6
pubmed: 10700177
Cells. 2019 Nov 13;8(11):
pubmed: 31766144
Radiat Res. 2014 Jan;181(1):1-8
pubmed: 24320053
Biol Direct. 2022 Jul 13;17(1):17
pubmed: 35831895
Mol Cell Proteomics. 2007 Mar;6(3):479-91
pubmed: 17151021
Cell Death Differ. 2022 Oct 1;:
pubmed: 36182991
ACS Med Chem Lett. 2015 Jul 06;6(8):856-60
pubmed: 26288684
Biochem Biophys Res Commun. 2010 Jun 25;397(2):192-6
pubmed: 20519146
FEBS J. 2014 Jul;281(13):2899-914
pubmed: 24802111
Biol Direct. 2021 Aug 6;16(1):14
pubmed: 34362419
Neoplasia. 2009 Jul;11(7):683-91
pubmed: 19568413
Oncogene. 2016 Nov 10;35(45):5893-5904
pubmed: 27065319
Mod Pathol. 2009 Apr;22(4):499-507
pubmed: 19151661
Biol Direct. 2022 Jan 8;17(1):3
pubmed: 34998421
J Biol Chem. 2017 Feb 3;292(5):1637-1647
pubmed: 27998979
Biol Direct. 2021 Nov 8;16(1):23
pubmed: 34749806
Clin Cancer Res. 2008 Sep 1;14(17):5348-56
pubmed: 18765526
Cell Biosci. 2015 Aug 18;5:44
pubmed: 26301083
Cancer Res. 2016 Sep 15;76(18):5405-14
pubmed: 27630139
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
Oncotarget. 2013 Feb;4(2):362-72
pubmed: 23482348
Sci Rep. 2019 Oct 29;9(1):15517
pubmed: 31664084
Biol Direct. 2021 Feb 8;16(1):7
pubmed: 33557857
Genes Dev. 2020 Jan 1;34(1-2):7-23
pubmed: 31896689
Oncotarget. 2016 May 31;7(22):33165-78
pubmed: 27121206
J Cell Sci. 2010 Apr 1;123(Pt 7):1020-30
pubmed: 20197409
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325